Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

Similar articles for PubMed (Select 17001523)

1.

Effects of a monoclonal anti-alphavbeta3 integrin antibody on blood vessels - a pharmacodynamic study.

Zhang D, Pier T, McNeel DG, Wilding G, Friedl A.

Invest New Drugs. 2007 Feb;25(1):49-55. Epub 2006 Sep 26.

PMID:
17001523
2.

Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion.

McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, Friedl A, Kolesar J, Marnocha R, Volkman J, Zhang J, Hammershaimb L, Zwiebel JA, Wilding G.

Clin Cancer Res. 2005 Nov 1;11(21):7851-60.

3.

Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin.

Mundhenke C, Thomas JP, Wilding G, Lee FT, Kelzc F, Chappell R, Neider R, Sebree LA, Friedl A.

Clin Cancer Res. 2001 Nov;7(11):3366-74.

4.

Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism.

Cai W, Chen X.

Anticancer Agents Med Chem. 2006 Sep;6(5):407-28. Review.

PMID:
17017851
5.

Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3.

Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ, Cheresh DA.

Clin Cancer Res. 2000 Aug;6(8):3056-61.

6.

Acute depletion of endothelial β3-integrin transiently inhibits tumor growth and angiogenesis in mice.

Steri V, Ellison TS, Gontarczyk AM, Weilbaecher K, Schneider JG, Edwards D, Fruttiger M, Hodivala-Dilke KM, Robinson SD.

Circ Res. 2014 Jan 3;114(1):79-91. doi: 10.1161/CIRCRESAHA.114.301591. Epub 2013 Oct 8.

8.

Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors.

Delbaldo C, Raymond E, Vera K, Hammershaimb L, Kaucic K, Lozahic S, Marty M, Faivre S.

Invest New Drugs. 2008 Feb;26(1):35-43. Epub 2007 Sep 18.

PMID:
17876527
9.
10.

Use of antibody as carrier of oligomers of peptidomimetic alphavbeta3 antagonist to target tumor-induced neovasculature.

Shin IS, Jang BS, Danthi SN, Xie J, Yu S, Le N, Maeng JS, Hwang IS, Li KC, Carrasquillo JA, Paik CH.

Bioconjug Chem. 2007 May-Jun;18(3):821-8. Epub 2007 Mar 22.

PMID:
17375899
11.
12.
13.

Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers.

White B, Leon F, White W, Robbie G.

Clin Ther. 2009 Apr;31(4):728-40. doi: 10.1016/j.clinthera.2009.04.019.

PMID:
19446146
15.

Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice.

Reinmuth N, Liu W, Ahmad SA, Fan F, Stoeltzing O, Parikh AA, Bucana CD, Gallick GE, Nickols MA, Westlin WF, Ellis LM.

Cancer Res. 2003 May 1;63(9):2079-87.

16.

Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy.

Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson KE, Saffrich R, Gröne HJ, Hallahan DE, Reisfeld RA, Debus J, Niethammer AG, Huber PE.

Clin Cancer Res. 2005 Sep 1;11(17):6270-9.

17.

Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin.

Mulgrew K, Kinneer K, Yao XT, Ward BK, Damschroder MM, Walsh B, Mao SY, Gao C, Kiener PA, Coats S, Kinch MS, Tice DA.

Mol Cancer Ther. 2006 Dec;5(12):3122-9.

18.
19.
20.

Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis.

Kumar CC.

Curr Drug Targets. 2003 Feb;4(2):123-31. Review.

PMID:
12558065
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk